by Matthew Huisman - National Law Journal
A Pfizer Inc. subsidiary on Tuesday entered into a $490.9 million settlement with the U.S. Department of Justice to resolve civil and criminal allegations of off-label pharmaceutical marketing abuses.'via Blog this'
The complaint alleged that Wyeth Pharmaceuticals Inc., acquired by Pfizer in 2009, illegally marketed its immunosuppressant drug Rapamune, which is intended to help kidney patients accept transplanted organs. From 1998 through 2009, Wyeth allegedly instructed sales representatives to promote the drug for unapproved uses to boost sales.
Read more: http://www.law.com/jsp/nlj/PubArticleNLJ.jsp?id=1202613118244&Wyeth_Settles_OffLabel_Marketing_Claims_for_4909_Million#ixzz2acwiRi7G